X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANI will commercialize a generic version of the reference-listed drug Fleqsuvy (baclofen). It is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain.
Lead Product(s): Baclofen
Therapeutic Area: Neurology Product Name: Fleqsuvy-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
Levaquin-Generic (levofloxacin) is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacterias. It is indicated for the treatment of pneumonia, acute bacterial sinusitis, chronic bacterial prostatitis & urinary tract infections in adults.
Lead Product(s): Levofloxacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Levaquin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.
Lead Product(s): Pentoxifylline
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Trental-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
Indocin-Generic (indomethacin) oral suspension is a COX inhibitor which is now approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis & acute gouty arthritis.
Lead Product(s): Indomethacin
Therapeutic Area: Immunology Product Name: Indocin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Cortrophin Gel (repository corticotropin injection) is an adrenocorticotropic hormone, which is indicated for acute gouty arthritis and rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; and ankylosing spondylitis.
Lead Product(s): Corticotropin
Therapeutic Area: Rheumatology Product Name: Cortrophin
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Estradiol tablets for oral administration, which is indicated for the treatment of moderate to severe vasomotor symptoms associated with the menopause.
Lead Product(s): Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Estrace-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
AB-101 is a novel, oral PD-L1 inhibitor, designed to allow for controlled checkpoint blockade, reawakens and boost the immune system of patients with chronic hepatitis B virus (cHBV).
Lead Product(s): AB-101
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Estradiol Gel, 0.1%, is the generic version of the Reference Listed Drug (RLD) Divigel®, an estrogen hormone therapy used to treat moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause.
Lead Product(s): Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Divigel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Methsuximide elevates the seizure threshold and reduces the frequency of attacks through depression of nerve transmission in the cortex.
Lead Product(s): Methsuximide
Therapeutic Area: Neurology Product Name: Celontin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
